Glenmark Pharmaceuticals plans to strengthen its US presence with more generic filings

22 Dec 2014 Evaluate

Glenmark Pharmaceuticals, a leading research-based global pharmaceutical company, is planning to strengthen its position in US, the world's largest drug market, by launching more generic copies. The company is currently in the process of filing a large number of ANDAs (Abbreviated New Drug Applications) with the US Food and Drug Administration (FDA). The company’s US formulations business, with sales of $335 million in FY14, contributes 34% to its consolidated revenues.

Glenmark Pharmaceuticals is a research-driven, global, integrated pharmaceutical company and ranked among the top 80 Pharma & Biotech companies of the world in terms of revenues as per SCRIP 100 Rankings. Glenmark has several molecules in various stages of clinical development and primarily focused in the areas of Inflammation, Pain and Oncology. The company has significant presence in branded formulations across emerging economies including India.

Glenmark Pharma Share Price

1965.75 -8.40 (-0.43%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×